Phase 2 RCT in 73 patients with pretreated HER2-positive, PAM50 luminal advanced breast cancer: palbociclib plus trastuzumab and endocrine therapy improved PFS vs trastuzumab-based physician's choice (HR 0.52); grade 3+ adverse events in 61.5%.
RCTn = 73
Ciruelos et al. Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial